Risk Subpoenas: Opening Statement and Pricing Policies

risk subpoenas: As the Finance Committee hearing got underway, Chairman Charles Grassley, R-Iowa, pointedly reminded the executives that it is a crime to provide false testimony to Congress, according to The Japan Times. Some of the companies initially had sought a private meeting to explain their pricing policies, but lawmakers refused and insisted the CEOs appear in public or risk subpoenas. ; Without a doubt, drug pricing is a complex issue, Grassley said in his prepared opening statement. The extraordinary public accounting was a sign that Congress and the White House are moving toward legislation this year to curb costs. But I think we should all be asking Should it be so complex We cannot allow anyone to hide behind the current complexities to shield the true cost of a drug. Ten companies accounted for half of all profits in the health care sector last fall. Ranking Democrat Ron Wyden of Oregon said in his prepared statement, You pharma executives are here because the way you do business is unacceptable and unsustainable. (news.financializer.com). As reported in the news.